Trial Profile
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MCS 2 (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Acronyms MCS_LUTS
- Sponsors Health Ever Bio-Tech
- 27 Nov 2015 New trial record